Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 13

Results For "2025"

870 News Found

Merck’s DOR/ISL regimen shows minimal impact on weight and lipids in phase 3 HIV studies
Clinical Trials | October 16, 2025

Merck’s DOR/ISL regimen shows minimal impact on weight and lipids in phase 3 HIV studies

These findings follow positive Phase 3 results presented earlier this year


Corning and SGD Pharma inaugurate glass tubing facility in Telangana
News | October 14, 2025

Corning and SGD Pharma inaugurate glass tubing facility in Telangana

The new plant will manufacture high-quality Type I borosilicate glass tubing


IPP organizes panel discussion on
Policy | October 13, 2025

IPP organizes panel discussion on "challenges and opportunities in Indian pharma sector" in Hyderabad on Oct. 15

Speakers are: Ch. A. P. Rameswara Rao, National President, BDMAI; Dr. Paidi Yella Reddy, Founder, President & CEO, Sapala Organics; K. V. Rama Gopal, Site Manager & Executive Director, Clariant India; Dr. K. Nagaiah, Chief Scientist, CSIR - Indian Institute of Chemical Technology, Hyderabad; Dr. Satyanarayana Thirunahari, Senior General Manager - Process Safety & Engineering, Laurus Labs; and Yadavendra Shalgaonkar, Assistant General Manager - Tube Sales, Alleima India


IPP organizes session on
Technology | October 13, 2025

IPP organizes session on "Combating Heat Exchanger Tube Corrosion in Pharma and Chemical Industry" on October 15 at Sheraton Hyderabad Hotel

Speakers for the Session are: Venkata Prasad K., Unit Head, Deepak Nitrite; Abhilash Pasham, Associate General Manager - Central Engineering & Projects, Dr. Reddy's Laboratories; C. V. Rajulu, Consultant, Industry; and Jyoti Shankar Jha, Senior Lead Scientist, Alleima India. The moderator for the Session is Pravin Prashant, Executive Editor, Indian Pharma Post


Relmada therapeutics appoints Dr. Max Kates to propel NDV-01 toward phase 3
People | October 13, 2025

Relmada therapeutics appoints Dr. Max Kates to propel NDV-01 toward phase 3

Phase 3 program for NDV-01 in non-muscle invasive bladder cancer expected to begin in the first half of 2026


Bristol Myers Squibb buys Orbital Therapeutics for $1.5 billion to strengthen cell therapy portfolio
News | October 12, 2025

Bristol Myers Squibb buys Orbital Therapeutics for $1.5 billion to strengthen cell therapy portfolio

Acquisition includes OTX-201, an investigational next-generation CAR T-cell therapy designed to reprogram cells in vivo with potential best-in-class profile for autoimmune diseases


AstraZeneca to lower cost of medicines for American patients
Policy | October 12, 2025

AstraZeneca to lower cost of medicines for American patients

AstraZeneca to invest $50bn in manufacturing and R&D to support domestic sourcing


Merck advances cancer innovation by expanding role of Keytruda across new tumor
R&D | October 11, 2025

Merck advances cancer innovation by expanding role of Keytruda across new tumor

The company will present new data from across over 20 cancer types and multiple treatment settings at European Society for Medical Oncology Congress 2025


Delhi High Court refuses to restrain Natco from manufacturing spinal muscular atrophy drug
News | October 10, 2025

Delhi High Court refuses to restrain Natco from manufacturing spinal muscular atrophy drug

The Court dismissed Swiss drugmaker Roche’s plea for interim injunction